about
Posttranslational Modifications and the Immunogenicity of BiotherapeuticsIsotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice.The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigenPhysiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeuticsGlycosylation profiling of therapeutic antibodies in serum samples using a microfluidic CD platform and MALDI-MS.High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzerFragmentation of monoclonal antibodiesN-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical.Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.Increased serum clearance of oligomannose species present on a human IgG1 molecule.Fast antibody fragment motion: flexible linkers act as entropic springSystemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.The maturation of antibody technology for the HIV epidemic.Post-translational structural modifications of immunoglobulin G and their effect on biological activity.Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.Antibody drug conjugates.Accumulation of secreted antibodies in plant cell cultures varies according to the isotype, host species and culture conditions.Assessment of disulfide and hinge modifications in monoclonal antibodiesB-cell responses to HIV infection.Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architectureEffects of blood processing and sample storage on the stability of biotherapeutics and anti-drug antibodies.Thiol-Disulfide Exchange in Human Growth Hormone.A high throughput capillary electrophoresis method to obtain pharmacokinetics and quality attributes of a therapeutic molecule in circulation.The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neckCharacterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: using LC-MS with electron transfer dissociation.Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.Analysis of isoaspartic Acid by selective proteolysis with Asp-N and electron transfer dissociation mass spectrometry.High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectromEngineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.Biosimilar, biobetter and next generation therapeutic antibodies6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies.Bioanalytical considerations in the comparability assessment of biotherapeutics.Viscosity Control of Protein Solution by Small Solutes: A Review.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.The road from development to approval: evaluating the body of evidence to confirm biosimilarity.IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development.Bridging immunogenicity assays for IgG4 therapeutics: mitigating interference from Fc-Fc interactions.
P2860
Q26748614-1BB63599-D842-40DC-A11E-00F3F419B973Q33751822-8859D0AF-90AD-47D9-8287-7FA9329ADFD0Q34212743-AFAC8881-3B13-4002-80ED-DD7670A25085Q34275537-60D2FC89-FB2C-4627-B0F3-3F4648BA4F85Q34697409-2AFE3B7E-3F39-4058-B1A4-CB8325AABA7EQ35019925-6FCD5212-7050-4E50-ACAA-9E574454BB0CQ35146070-DB00D731-B342-4B74-9AAE-570CD21EC481Q36133312-3B20693F-45C5-491B-BAA6-4CF9C40B5619Q36402805-82146269-58F3-496C-B5AD-08721CE1427BQ36402812-BE47E6E5-F0CE-423B-B920-666E484FFC11Q36735921-5380F82F-4089-4D18-89B8-2A7B247F03D8Q37338339-9099C727-B67B-4DBC-B77B-71084D1B2EAAQ37999739-40C1E5AD-A699-4658-B38D-EEE44ED9A071Q38209477-9D04766B-790C-4AC1-B420-DAD915460344Q38246996-9724463B-A113-4EEB-9965-09767E57D7D8Q38602178-594C294A-E887-484C-A765-7232B1556529Q38873862-9DD3C630-EA85-4295-B48B-2C832844E30BQ39039076-1D33FF09-B489-44A3-AFF0-AC3D97855CFEQ39041113-C6712D7D-E49A-48EC-8607-082A87519D2BQ39108710-2791ED8B-F40D-4D7B-B1A7-AFCC213232A8Q39970297-529068EE-F082-4470-A2ED-0D52619FA4CCQ40797836-F172936C-6BC4-4FBA-A9FF-07FB090E187AQ40929419-F2C6764D-6087-4603-917E-02C0FCF75D54Q41121902-78AD54E8-BED3-40ED-B14D-08ADDC367037Q41513098-DB893C77-1A82-40C3-AC00-E3DA5050A37EQ41824023-20B53286-B91C-4EFF-8756-0B084C53F06FQ41913558-83CB79B2-0971-4A9C-AB66-21045D0E6AD8Q41970463-A97FCB37-CE3E-4E57-ACDC-81051A33BD9EQ42118236-2841CFBF-F244-40E4-B27F-52C6FB3E4948Q42234345-46FE40A8-7BBF-4D68-B7A2-A648B6944D1EQ42732007-CD103DA7-F7F9-48E2-B455-0F4229ED7CC2Q42732008-A63D4510-C00C-4C05-BEC4-76E734B96A74Q43660922-9F8364FA-3713-41E4-8123-8849D45F3098Q43764396-41E74AA6-A55F-42DE-A580-3FA5B9EB8027Q44701500-3E041CBD-C357-4CDD-80EB-764CEEE10822Q47297020-5D7F0DF2-02B7-4144-834A-70C641328243Q47807650-128F100F-362D-46C0-A20C-8BE24A42B576Q47950956-C1DF0557-B935-4C2F-8D8D-5DC850E39D93Q49816574-7FF14DF8-D64B-47D9-9B13-65EC2B15251FQ50659174-B831E10F-B172-4D1F-9C24-2CCC516933F6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Stability of IgG isotypes in serum.
@en
Stability of IgG isotypes in serum.
@nl
type
label
Stability of IgG isotypes in serum.
@en
Stability of IgG isotypes in serum.
@nl
prefLabel
Stability of IgG isotypes in serum.
@en
Stability of IgG isotypes in serum.
@nl
P2860
P356
P1476
Stability of IgG isotypes in serum.
@en
P2093
Ivan R Correia
P2860
P304
P356
10.4161/MABS.2.3.11788
P577
2010-05-16T00:00:00Z